CAR-T-Zell-Therapie – personalisierte zelluläre Immuntherapie im Jahr 2022

Chimäre Antigen-Rezeptor-T-Zellen (CAR-T-Zellen) sind genetisch modifizierte autologe oder allogene T-Lymphozyten, die sich gegen spezifische Antigene richten und z. B. zur Bekämpfung von Tumorzellen eingesetzt werden können. Die Zulassungsstudien zeigen eine hohe Ansprech- und Remissionsrate bei massiv vorbehandelten Patient*innen mit aggressiven B-Zell-Lymphomen, akuter lymphoblastischer Leukämie oder Multiplem Myelom. Der Beitrag stellt die Zulassungsindikationen, die klinische Durchführung und das Management der Nebenwirkungen der CAR-Zell-Therapie vor.

Abstract

Chimeric antigen receptor T cells (CAR T cells) are genetically modified autologous or allogeneic T lymphocytes that target specific antigens and can be used to combat tumor cells. The approval studies show a high response and remission rate in heavily pretreated patients with aggressive B-cell lymphoma, acute lymphoblastic leukemia or multiple myeloma. The article presents the indications for approval, the clinical implementation and the management of side effects of CAR cell therapy.

Schlüsselwörter

chimäre Antigen-Rezeptor-T-Zellen - CAR-T-Zellen - Zulassungsstudien - Real-World Daten

Key words

chimeric antigen receptor T cells - CAR T cells - registration studies - real world data

Publication History

Article published online:
16 November 2022

• Literatur

• 1 Kolb HJ. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT immunology and chronic leukemia working parties. Vox Sang 1998; 74 (Suppl. 02) 321-329
• 2 Park JH, Geyer MB, Brentjens RJ. et al. CD19-targeted CAR T cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood 2016; 127 (26) 3312-3320
• 3 Schuster SJ, Bishop MR, Tam CS. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. New Engl J Med 2019; 380: 45-56
• 4 Maude SL, Laetsch TW, Buechner J. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New Engl J Medicine 2018; 378: 439-448
• 5 Neelapu SS, Locke FL, Bartlett NL. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017; 377 (26) 2531-2544
• 6 Abramson JS, Palomba ML, Gordon LI. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 2020; 396: 839-852
• 7 Wang M, Munoz J, Goy A. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2020; 382: 1331-1342
• 8 Munshi NC, Anderson LD, Shah N. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021; 384 (08) 705-716
• 9 Bethge WA, Martus P, Schmitt M. et al. GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. Blood 2022
• 10 Shimabukuro-Vornhagen A, Goedel P, Subklewe M. et al. Cytokine release syndrome. J Immunother Cancer 2018; 06: 56
• 11 Onkopedia Leitlinie. CAR-T-Zellen: Management von Nebenwirkungen (Juni 2020). Zugriff am 06.02.2022 unter https://www.onkopedia.com/de/onkopedia/guidelines/car-t-zellenmanagement-von-nebenwirkungen
• 12 Lee DW, Santomasso BD, Locke FL. et al. ASTCT consensus grading for cytokine release syndrome and neurological toxicity associated with immune effector cells. Biol Blood Marrow Tr 2019; 25 (04) 625-638
• 13 Fried S, Avigdor A, Bielorai B. et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transpl 2019; 54: 1643-1650
• 14 Gemeinsamer Bundesausschuss – G-BA. Zusammenfassende Dokumentation zum Beschluss des Gemeinsamen Bundesausschusses über Maßnahmen zur Qualitätssicherung bei der Anwendung von CAR-T-Zellen bei B-Zell Neoplasien nach § 136a Absatz 5 Sozialgesetzbuch Fünftes Buch (SGB V) und zur Änderung der Anlage XII zur Arzneimittelrichtlinie (AMRL). Gemeinsamber Bundesausschuss, 17. September 2020. Zugriff am 04.07.2022 unter https://www.g-ba.de/downloads/40-268-6894/2020-09-17_AM-RL_CarT-Zellen-QS-Maßnahmen_ZD.pdf
• 15 Locke FL, Miklos DB, Jacobson CA. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022; 386: 640-654
• 16 ClinicalTrials.gov. A study to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (TRANSFORM). (Letztes Update 10.06.2021). Zugriff am 20.02.2022 unter https://clinicaltrials.gov/ct2/show/NCT03575351
• 17 Bishop MR, Dickinson M, Purtill D. et al. Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed aggressive B-cell non-Hodgkin lymphoma: analysis of the phase III Belinda study. Abstract LBA-6. Presented at the 2021 ASH Annual Meeting 2021;
• 18 Thieblemont C, Dickinson M, Martinez-Lopez J. et al. Efficacy of tisagenlecleucel in adult patients (Pts) with high-risk relapsed/refractory follicular lymphoma (r/r FL): subgroup analysis of the phase II Elara study. Blood 2021; 138 (Suppl. 01) 131
• 19 Fry TJ, Shah NN, Orentas RJ. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 2018; 24 (01) 20-28
• 20 Tong C, Zhang Y, Liu Y. et al. Optimized tandem CD19 / CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood 2020; 136 (14) 1632-1644
• 21 Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther 2015; 15 (08) 1145-1154
• 22 Abramson S, Palomba ML, Gordon LI. et al. Two-year follow-up of transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-Cell lymphomas (LBCL). Blood 2021; 138 (Suppl. 01)